THE ROLE OF CYTOMEGALOVIRUS PHOSPHOPROTEIN 65 IN VIRUS REPLICATON IN VIVO
巨细胞病毒磷酸蛋白65在体内病毒复制中的作用
基本信息
- 批准号:7958465
- 负责人:
- 金额:$ 3.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-04 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:AnimalsAntiviral AgentsCapsidCellular ImmunityChronicComputer Retrieval of Information on Scientific Projects DatabaseCytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesCytoplasmDevelopmentFundingGrantGrowthImmune responseIn VitroInfectionInstitutionMacacaMacaca mulattaOutcomePrimatesProteinsResearchResearch PersonnelResourcesRoleSourceUnited States National Institutes of HealthVirusVirus DiseasesVirus Replicationcytomegalovirus matrix protein 65kDadesignimmunogenicityin vivomutantvector vaccine
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Cytomegalovirus (CMV) protein pp65 modulates the host immune response yet simultaneously is the primary antiviral target of cellular immunity. pp65 is the most abundant component of the Rhesus CMV (RhCMV) and human CMV (HCMV) tegument, a protein-rich layer between the capsid and the envelope that is released into the cytoplasm. Interestingly, pp65 is not required for in vitro growth of either virus. This allowed us to generate a pp65-deficient RhCMV to examine whether 1) pp65's immunomodulatory functions are critical for virus survival in vivo; or 2) pp65 immunogenicity limits virus replication in healthy animals. Infection of rhesus macaques (RMs) with mutant RhCMV will allow examination of the importance of pp65 for CMV infection in vivo. We will infect CMV-na¿ve macaques with pp65-deleted RhCMV and evaluate whether this virus is able to establish primary and chronic infection and, if so, how virological and immunological parameters compare to previous observations made during infection with wild type RhCMV. Depending on the outcome, we will evaluate whether pp65-deleted virus is able to re-infect these animals. If pp65-encoded functions are required for productive infection, we expect replication of the mutant to be either undetectable or diminished. Conversely, if pp65 immunogenicity is crucial to the ability of the host immune response to control virus infection we predict that replication of the pp65-deleted virus will be greater than that for wild type. The outcome has implications both for the design of CMV vaccines and antivirals as well as the development of CMV as a vaccine vector.
这个子项目是许多研究子项目中的一个
由NIH/NCRR资助的中心赠款提供的资源。子项目和
研究者(PI)可能从另一个NIH来源获得了主要资金,
因此可以在其他CRISP条目中表示。所列机构为
研究中心,而研究中心不一定是研究者所在的机构。
巨细胞病毒(CMV)蛋白pp 65调节宿主免疫应答,但同时是细胞免疫的主要抗病毒靶点。pp 65是恒河猴CMV(RhCMV)和人CMV(HCMV)被膜的最丰富的组分,所述被膜是衣壳和被膜之间释放到细胞质中的富含蛋白质的层。有趣的是,这两种病毒的体外生长都不需要pp 65。这使我们能够产生pp 65缺陷型RhCMV,以检查1)pp 65的免疫调节功能是否对病毒在体内的存活至关重要;或2)pp 65免疫原性是否限制病毒在健康动物中的复制。用突变型RhCMV感染恒河猴(RM)将允许检查pp 65对于体内CMV感染的重要性。我们会感染CMV病毒的用pp 65缺失的RhCMV感染猕猴,评估这种病毒是否能够建立原发性和慢性感染,如果是,病毒学和免疫学参数如何与野生型RhCMV感染期间的先前观察结果进行比较。根据结果,我们将评估pp 65缺失病毒是否能够重新感染这些动物。如果pp 65编码的功能是生产性感染所必需的,我们预计突变体的复制要么检测不到,要么减少。相反,如果pp 65免疫原性对宿主免疫应答控制病毒感染的能力至关重要,我们预测pp 65缺失病毒的复制将大于野生型。该结果对CMV疫苗和抗病毒药物的设计以及CMV作为疫苗载体的开发都有影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VICTOR Robert DEFILIPPIS其他文献
VICTOR Robert DEFILIPPIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VICTOR Robert DEFILIPPIS', 18)}}的其他基金
A Self-Adjuvanting Virus Like Particle Vaccine Platform for Emerging Viruses
针对新兴病毒的自我佐剂病毒样颗粒疫苗平台
- 批准号:
10711617 - 财政年份:2023
- 资助金额:
$ 3.45万 - 项目类别:
Anti-tumor efficacy of novel cGAS-STING pathway agonists
新型 cGAS-STING 通路激动剂的抗肿瘤功效
- 批准号:
10286612 - 财政年份:2021
- 资助金额:
$ 3.45万 - 项目类别:
Anti-tumor efficacy of novel cGAS-STING pathway agonists
新型 cGAS-STING 通路激动剂的抗肿瘤功效
- 批准号:
10430274 - 财政年份:2021
- 资助金额:
$ 3.45万 - 项目类别:
Mechanistic Exploration of cGAS-STING-Mediated Vaccine Enhancement
cGAS-STING 介导的疫苗增强机制探索
- 批准号:
10318966 - 财政年份:2019
- 资助金额:
$ 3.45万 - 项目类别:
Mechanistic Exploration of cGAS-STING-Mediated Vaccine Enhancement
cGAS-STING 介导的疫苗增强机制探索
- 批准号:
10534676 - 财政年份:2019
- 资助金额:
$ 3.45万 - 项目类别:
THE ROLE OF CYTOMEGALOVIRUS PHOSPHOPROTEIN 65 IN VIRUS REPLICATON IN VIVO
巨细胞病毒磷酸蛋白65在体内病毒复制中的作用
- 批准号:
7715956 - 财政年份:2008
- 资助金额:
$ 3.45万 - 项目类别:
THE ROLE OF CYTOMEGALOVIRUS PHOSPHOPROTEIN 65 IN VIRUS REPLICATON IN VIVO
巨细胞病毒磷酸蛋白65在体内病毒复制中的作用
- 批准号:
7561989 - 财政年份:2007
- 资助金额:
$ 3.45万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 3.45万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 3.45万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 3.45万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 3.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 3.45万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 3.45万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 3.45万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 3.45万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 3.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 3.45万 - 项目类别: